Related Experiment Video
Updated: Jan 12, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.8K
Advances in Tissue-Agnostic Targeting in Cancer Therapeutics: Current Approvals, Challenges, and Future Directions
Matthew Rubinstein1, Madeline Lauren Hong1, Rishi Kumar Nanda1
1College of Osteopathic Medicine, Touro University, Henderson, NV 89014, USA.
Oncology Research
|November 3, 2025
Summary
Tissue-agnostic therapies, targeting cancer mutations regardless of origin, are revolutionizing oncology. Research is ongoing to maximize patient benefit and overcome challenges like tumor heterogeneity and resistance for broader access.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- Tissue-agnostic therapies target specific mutations, not tumor location, transforming cancer treatment.
- These therapies represent a significant shift towards precision oncology, offering new hope for diverse patient populations.
Purpose of the Study:
- To review the impact, safety, and challenges of emerging tissue-agnostic therapies.
- To explore strategies for refining patient selection and improving access to biomarker testing.
- To highlight the role of pan-histological biomarkers in guiding treatment decisions.
Main Methods:
- Literature review of current tissue-agnostic therapies and clinical trials.
- Analysis of therapeutic efficacy, safety profiles, and resistance mechanisms.
- Discussion of biomarker development and patient selection strategies.
Main Results:
- Tissue-agnostic therapies show effectiveness across various cancer types, offering significant patient benefits.
- Challenges include intratumoral heterogeneity and acquired resistance, impacting long-term efficacy.
- Emerging biomarkers like neoantigen burden are crucial for patient stratification.
Conclusions:
- Tissue-agnostic therapies are a transformative advancement in precision oncology.
- Ongoing research is essential to optimize treatment strategies and overcome access barriers.
- Improving biomarker testing accessibility is key to realizing the full potential of these therapies.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K